🇺🇸 FDA

Company profile · Sponsor

CORCEPT

CORCEPT THERAPEUTICS INC

CORT · NYSE pharma REDWOOD CITY, CA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

CORCEPT (CORT) is a pharma company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker CORT
Exchange NYSE
Company type pharma
Headquarters REDWOOD CITY, CA, USA
SEC CIK 0001088856

Pipeline (24)

Search pipeline →

  1. An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

    CORCEPT

    Endogenous Cushing Syndrome

    phase 3 other active

    1 trial

  2. Mifepristone

    CORCEPT

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  3. Nab-paclitaxel 80 mg/m^2

    CORCEPT

    Ovarian Neoplasm

    phase 3 small molecule active

    1 trial

  4. Relacorilant

    CORCEPT

    Hypercortisolism

    phase 3 small molecule completed

    1 trial

  5. Relacorilant, 100 mg and 25 mg

    CORCEPT

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  6. mifepristone

    CORCEPT

    Psychotic Depression

    phase 3 small molecule terminated

    1 trial

  7. mifepristone

    CORCEPT

    Cushing's Syndrome

    phase 3 small molecule completed

    2 trials

  8. mifepristone

    CORCEPT

    Cushing's Disease

    phase 3 small molecule terminated

    2 trials

  9. mifepristone

    CORCEPT

    Major Depressive Disorder

    phase 3 small molecule completed

    5 trials

  10. relacorilant

    CORCEPT

    Cushing Syndrome

    phase 3 small molecule active

    2 trials

  11. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  12. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  13. CORT125134

    CORCEPT

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  14. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  15. Dazucorilant 300 mg

    CORCEPT

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  16. Enzalutamide

    CORCEPT

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Exicorilant

    CORCEPT

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  18. Mifepristone

    CORCEPT

    Weight-Gain Prevention

    phase 2 small molecule completed

    1 trial

  19. Mifepristone

    CORCEPT

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  20. Mifepristone

    CORCEPT

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  21. Mifepristone

    CORCEPT

    Central Adrenal Insufficiency

    phase 2 small molecule terminated

    1 trial

  22. Mifepristone 1200 mg daily

    CORCEPT

    Treatment-resistant PTSD

    phase 2 small molecule active

    1 trial

  23. Miricorilant

    CORCEPT

    Antipsychotic-induced Weight Gain (AIWG)

    phase 2 small molecule completed

    1 trial

  24. Miricorilant

    CORCEPT

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

Drugs (1)

Search drugs →

  1. relacorilant

    LIFYORLI (COPACKAGED)

    ORAL approved

Patents (8)

Search patents →

  1. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12336985

    Methods for shrinking pituitary tumors

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is CORCEPT?

CORCEPT (CORT) is a pharma company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does CORCEPT sponsor?

We track 24 ClinicalTrials.gov-linked programs for CORCEPT, including An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CORCEPT company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.